Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • View or Listen to JNM Podcast
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Follow JNM on Twitter
  • Subscribe to our RSS feeds
Research ArticleNuclear Oncology

Technetium-99m-MIBI Versus Fluorine-18-FDG in Diffuse Multiple Myeloma

Ayda M. El-Shirbiny, Henry Yeung, Massimo Imbriaco, Joseph Michaeli, Homer Macapinlac and Steven M. Larson
Journal of Nuclear Medicine August 1997, 38 (8) 1208-1210;
Ayda M. El-Shirbiny
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Henry Yeung
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Massimo Imbriaco
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Joseph Michaeli
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Homer Macapinlac
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Steven M. Larson
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
  • PDF
Loading
PDF extract preview

This is a PDF-only article. The first page of the PDF of this article appears above.

PreviousNext
Back to top

In this issue

Journal of Nuclear Medicine
Vol. 38, Issue 8
August 1, 1997
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Advertising (PDF)
  • Back Matter (PDF)
  • Ed Board (PDF)
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Technetium-99m-MIBI Versus Fluorine-18-FDG in Diffuse Multiple Myeloma
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
Technetium-99m-MIBI Versus Fluorine-18-FDG in Diffuse Multiple Myeloma
Ayda M. El-Shirbiny, Henry Yeung, Massimo Imbriaco, Joseph Michaeli, Homer Macapinlac, Steven M. Larson
Journal of Nuclear Medicine Aug 1997, 38 (8) 1208-1210;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Technetium-99m-MIBI Versus Fluorine-18-FDG in Diffuse Multiple Myeloma
Ayda M. El-Shirbiny, Henry Yeung, Massimo Imbriaco, Joseph Michaeli, Homer Macapinlac, Steven M. Larson
Journal of Nuclear Medicine Aug 1997, 38 (8) 1208-1210;
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • Assessment of whole body MRI and sestamibi technetium-99m bone marrow scan in prediction of multiple myeloma disease progression and outcome: a prospective comparative study
  • Imaging of Multiple Myeloma and Related Plasma Cell Dyscrasias
  • 18F-FDG PET/CT, 99mTc-MIBI, and MRI in Evaluation of Patients with Multiple Myeloma
  • Imaging of Malignant Bone Involvement by Morphologic, Scintigraphic, and Hybrid Modalities
  • Combined Use of 99mTc-Sestamibi and 99mTc-V-DMSA in the Assessment of Chemotherapy Effectiveness in Patients with Multiple Myeloma
  • Whole-Body 18F-FDG PET Identifies High-Risk Myeloma
  • Google Scholar

More in this TOC Section

  • Radiotoxicity After Strontium-89 Therapy for Bone Metastases Using the Micronucleus Assay
  • Lymphoscintigraphy and Radioguided Biopsy of the Sentinel Axillary Node in Breast Cancer
  • Fluorine-18-Fluorodeoxyglucose PET Identification of Cardiac Metastasis Arising from Uterine Cervical Carcinoma
Show more Nuclear Oncology

Similar Articles

SNMMI

© 2025 SNMMI

Powered by HighWire